Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12609000091202
Ethics application status
Approved
Date submitted
18/12/2008
Date registered
10/02/2009
Date last updated
10/02/2009
Type of registration
Retrospectively registered

Titles & IDs
Public title
The use of tiagabine and gabapentin in the treatment of social anxiety disorder in 8 patients
Scientific title
Gabapentin and tiagabine for treatment of social anxiety disorder in 8 patients in a random double blind crossover study with outcome measured as changes in the Leibowitz Social Anxiety Scale
Secondary ID [1] 771 0
Nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Subjects with social anxiety disorder 4141 0
Condition category
Condition code
Mental Health 4344 4344 0 0
Anxiety

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Each subject was titrated to either 1800 mg gabapentin oral tablets daily or 2400 mg tiagabine oral tablets daily by mouth and stayed at that dosage for 4 weeks before being washed out for 2 weeks and receiving whichever medication they had not initially received.
Intervention code [1] 3855 0
Treatment: Drugs
Comparator / control treatment
This study was a randomized double blind crossover study so that each subject was its own control
Control group
Active

Outcomes
Primary outcome [1] 5223 0
Liebowitz Social Anxiety Scale: social anxiety
Timepoint [1] 5223 0
Measured at 2 weeks, 4 weeks, 8 weeks, 10 weeks, 14 weeks, and 16 weeks after randomization
Secondary outcome [1] 8806 0
Clinical Global impression scale: severity of illness and global functioning
Timepoint [1] 8806 0
Measured at 2 weeks, 4 weeks, 8 weeks, 10 weeks, 14 weeks, and 16 weeks after randomization

Eligibility
Key inclusion criteria
diagnosis of social anxiety disorder by DSM-IV criterial and a Liebowitz Socail Anxiety Scale greater than 30.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Other Axis I psychiatric disorders, major medical illnesses, taking medications that interacted with the study drugs, actively using alcohol or illegal drugs, were pregnant, planning to become pregnant, or breastfeeding

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment was done by a research coordinator who had no contact with subjects. The research coordinator put the study medication in a sealed opaque envelope for the investigator who did not know the contents of the envelope for distribution to the subject.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomization by using a randomization table from a statistics book
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 2 / Phase 3
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
20/05/2003
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
8
Accrual to date
Final
Recruitment outside Australia
Country [1] 1478 0
United States of America
State/province [1] 1478 0
VA

Funding & Sponsors
Funding source category [1] 4310 0
Charities/Societies/Foundations
Name [1] 4310 0
Norfolk Foundation
Country [1] 4310 0
United States of America
Primary sponsor type
Individual
Name
Maria Urbano, M.D.
Address
Dept. of Psychiatry
Eastern Virginia Medical School
825 Fairfax Ave.
Norfolk VA
United States 23507
Country
United States of America
Secondary sponsor category [1] 3882 0
Individual
Name [1] 3882 0
David R. Spiegel, M.D.
Address [1] 3882 0
Dept. of Psychiatry
Eastern Virginia Medical School
825 Fairfax Ave.
Norfolk VA
United States 23507
Country [1] 3882 0
United States of America

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 6357 0
Eastern Virginia Medical School Institutional Review Board
Ethics committee address [1] 6357 0
Eastern Virginia Medical School
P.O. Box 1980
Norfolk VA 23510
Ethics committee country [1] 6357 0
United States of America
Date submitted for ethics approval [1] 6357 0
Approval date [1] 6357 0
24/08/2006
Ethics approval number [1] 6357 0
05-06-FB-0140

Summary
Brief summary
Social Anxiety Disorder creates stress and significant disability for patients. Common treatments like selective serotonin reuptake inhibitors and benzodiazepines have undesirable side effects like sexual dysfunction or the potential for drug abuse/ dependence. The objective of the study was to see if alternative medications - tiagabine and gabapentin - already shown to be effective in other anxiety disorders might be effective for social anxiety disorder too. Subjects were selected to have social anxiety disorder by meeting the DSM-IV criteria and having a high score on the Liebowitz Social Anxiety Scale. Subjects were chosen who were generally healthy and had no other psychiatric diagnoses. They received a physical exam and lab work before starting the study. Each individual received each medication at a steady dosage for 4 weeks after being slowly increased for two weeks. The subjects took a Liebowitz Social Anxiety Scale and Clinical Global Impression Scale on each visit as well as reported efficacy of the medication (unknown to the patient or the investigator) and any side effects. Eight patients completed the study. Both medications were well tolerated with sedation and mild dizziness being the most common. All subjects with severe social anxiety responded well to both medications with two subjects reaching remission of symptoms. Gabapentin and tiagabine should be considered as effective alternate treatments for social anxiety disorder.
Trial website
Trial related presentations / publications
Gabapentin and Tiagabine for Social Anxiety Disorder: A Randomized, Double Blind Crossover Study of 8 Adults
This paper has been submitted and accepted for publication in the Primary Care Companion of the Journal of Clinical Psychiatry. It has not been assigned a publication date.
Public notes

Contacts
Principal investigator
Name 35047 0
Address 35047 0
Country 35047 0
Phone 35047 0
Fax 35047 0
Email 35047 0
Contact person for public queries
Name 12394 0
Maria R. Urbano, M.D.
Address 12394 0
Dept. of Psychiatry
Eastern Virginia Medical School
825 Fairfax Ave.
Norfolk VA United States of America
23507
Country 12394 0
United States of America
Phone 12394 0
1-757-446-5888
Fax 12394 0
1-757-446-5918
Email 12394 0
[email protected]
Contact person for scientific queries
Name 3322 0
Maria R. Urbano, M.D.
Address 3322 0
Dept. of Psychiatry
EasternVirginia Medical School
825 Fairfax Ave.
Norfolk VA United States of America
23507
Country 3322 0
United States of America
Phone 3322 0
1-757-446-5888
Fax 3322 0
1-757-446-5918
Email 3322 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.